Program
taladegib
Also written as “LY2940680”, “ENV-101 (taladegib)” and “ENV-101”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Laryngeal Diseases · Neoplasms · Neoplasm Metastasis · Small Cell Lung Carcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 60 open or running | phase 2since Nov 2, 2012 | Oct 20, 2010 | none ahead |
| Endeavor Biomedicines | 52 open or running | phase 2since Jun 29, 2021 | Jun 29, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2010First study: phase 1 study in NeoplasmsNew to Eli LillyEli Lilly · NCT01226485 · 84 enrolled · United States
- Sep 4, 20122 phase 1 studiesEli Lilly · NCT01681186, NCT01697514
- Nov 2, 2012Phase 2 study in Small Cell Lung CarcinomaEli Lilly · NCT01722292 · 26 enrolled · United States, United Kingdom
- Dec 7, 2012Phase 1 study in Healthy VolunteersEli Lilly · NCT01746745 · 6 enrolled · United States
- Aug 5, 2013Phase 1 study in Neoplasm MetastasisEli Lilly · NCT01919398 · 19 enrolled · Japan
- Jun 29, 2021Endeavor Biomedicines's first study: phase 2 study in Idiopathic Pulmonary FibrosisNew to Endeavor BiomedicinesEndeavor Biomedicines · NCT04968574 · 41 enrolled · Australia, Canada, Korea, Republic of and more
- Dec 14, 2021Phase 2 study in Laryngeal DiseasesEndeavor Biomedicines · NCT05199584 · 20 enrolled · United States
- Apr 5, 2023Phase 1 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT05817240 · 21 enrolled · Australia
- May 15, 2024Phase 2 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT06422884 · 213 enrolled · Argentina, Australia, Austria and more
- Mar 2, 2026Phase 1 study in Idiopathic Pulmonary FibrosisEndeavor Biomedicines · NCT07454291 · 57 planned · Australia
TargetBeta
“Smoothened homolog antagonist”ChEMBL 37, by rule
Other programs on SMO
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sonidegibrule | Novartis | phase 4 | 16 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07454291Idiopathic Pulmonary Fibrosis · Australia | 1 | Recruiting | Endeavor Biomedicines | Oct 2026 | 57 |
| NCT06422884Idiopathic Pulmonary Fibrosis · Argentina, Australia, Austria and more | 2 | Active, not recruiting | Endeavor Biomedicines | Oct 2026 | 213 |
| NCT05817240Idiopathic Pulmonary Fibrosis · Australia | 1 | Completed | Endeavor Biomedicines | Jun 11, 2023 | 21 |
| NCT05199584Laryngeal Diseases · United States | 2 | Completed | Endeavor Biomedicines | Feb 20, 2024 | 20 |
| NCT04968574Idiopathic Pulmonary Fibrosis · Australia, Canada, Korea, Republic of and more | 2 | Completed | Endeavor Biomedicines | Nov 30, 2023 | 41 |
| NCT01919398Neoplasm Metastasis · Japan | 1 | Completed | Eli Lilly | May 2016 | 19 |
| NCT01746745Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Mar 2013 | 6 |
| NCT01722292Small Cell Lung Carcinoma · United States, United Kingdom | 2 | Terminated | Eli Lilly | Feb 2015 | 26 |
| NCT01697514Medulloblastoma · United States | 1 | Withdrawn | Eli Lilly | Jul 2016 | 0 |
| NCT01681186Healthy Participants · United States | 1 | Completed | Eli Lilly | Dec 2012 | 30 |
| NCT01226485Neoplasms · United States | 1 | Completed | Eli Lilly | Jan 2015 | 84 |
How it is read
Names in the registry
- “LY2940680”, 4 entries
- “taladegib”, 3 entries
- “ENV-101 (taladegib)”, 1 entry
- “ENV-101”, 1 entry
- “LY2940680 Capsule(s) (Reference)”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 4 studies
- Laryngeal Diseases, 1 study
- Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.